Related Experiment Video
Updated: Aug 29, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The
Jack L Martin1, Edward T A Fry, Ger-Jan C M Sanderink
1John S. Sharpe Research Foundation, Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, USA. martinj@mlhs.org
Abstract:
The objective of this study was to evaluate the pharmacokinetic response to intravenous (IV) enoxaparin given 8-12 hr after subcutaneous (SC) dosing in patients undergoing percutaneous coronary intervention (PCI). Fifty-five patients received SC enoxaparin (1 mg/kg every 12 hr) followed by an IV bolus (0.3 mg/kg) 8-12 hr after the last SC dose, at the start of PCI or during catheterization. Anti-Xa levels were within the target range in 98% of patients 2-8 hr after the last SC dose, in 96% of patients following the IV bolus, and in 91% of patients for a further 2 hr. Subcutaneous enoxaparin (1 mg/kg every 12 hr) provides sufficient anti-Xa levels for PCI 2-8 hr after the last dose. An additional 0.3 mg/kg enoxaparin dose given IV 8-12 hr after the last SC dose reliably maintains anti-Xa levels within the target for at least 2 additional hr.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Cardiac Catheterization I: Pre-Procedure Overview
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
